154590-33-7

Basic information

• Product Name: 1-(2-Fluoro-4-nitrophenyl)piperazine
• Synonyms: BUTTPARK 153\33-48;1-(2-FLUORO-4-NITROPHENYL)PIPERAZINE;Piperazine, 1-(2-fluoro-4-nitrophenyl)-
• CAS NO: 154590-33-7
• Molecular Formula: C₁₀H₁₂FN₃O₂
• Molecular Weight: 225.22
• Mol File: 154590-33-7.mol

Chemical Properties

• Melting Point: 70-72°C
• Boiling Point: 392.728 °C at 760 mmHg
• Flash Point: 191.315 °C
• Appearance: /Solid
• Density: 1.296 g/cm³
• Vapor Pressure: 2.24E-06mmHg at 25°C
• Refractive Index: 1.561
• PKA: 8.50±0.10(Predicted)
• CAS DataBase Reference: 1-(2-Fluoro-4-nitrophenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Fluoro-4-nitrophenyl)piperazine(154590-33-7)
• EPA Substance Registry System: 1-(2-Fluoro-4-nitrophenyl)piperazine(154590-33-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 154590-33-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Fluoro-4-nitrophenyl)piperazine is used as an intermediate for the synthesis of Eperezolid (E565740), an anti-infective agent. Its unique chemical structure allows for the development of new drugs with improved antimicrobial properties, targeting a wide range of bacterial infections.
Used in Antimicrobial Applications:
1-(2-Fluoro-4-nitrophenyl)piperazine is utilized in the creation of Eperezolid (E565740), which exhibits potent antimicrobial activity. 1-(2-Fluoro-4-nitrophenyl)piperazine is particularly effective against various strains of bacteria, making it a valuable asset in the fight against antibiotic-resistant infections. Its development contributes to the ongoing efforts to discover new and effective treatments for bacterial diseases.

InChI:InChI=1/C10H12FN3O2/c11-9-7-8(14(15)16)1-2-10(9)13-5-3-12-4-6-13/h1-2,7,12H,3-6H2

Upstream product

• 154590-34-8 4-(2-fluoro-4-nitrophenyl)-piperazine-1-carboxylic acid tert butyl ester 
• 110-85-0 piperazine 
• 369-34-6 3,4-difluoronitrobenzene 

Downstream Products

• 1000052-37-8 1-[4-(2-fluoro-4-nitrophenyl)piperazin-1-yl]propan-2-one 
• 403735-83-1 1-[4-(2-fluoro-4-nitrophenyl)piperazin-1-yl]propan-1-one 
• 1126430-24-7 1-(2-fluoro-4-nitrophenyl)-4-(2-fluoroethyl)piperazine 
• 1163126-60-0 (4-(2-fluoro-4-nitrophenyl)piperazin-1-yl)(phenyl)acetonitrile 
• 935855-76-8 [4-(2-fluoro-4-nitro-phenyl)-piperazin-1-yl]-phenyl-acetic acid 
• 1163126-46-2 1-(2-fluoro-4-nitrophenyl)-4-(oxazol-2-yl(phenyl)methyl)piperazine 
• 1147846-99-8 ethyl 4-(4-(2-fluoro-4-nitrophenyl)piperazin-1-yl)-2-oxo-6-phenylcyclohex-3-ene-1-carboxylate 
• 1147846-97-6 ethyl 4-(4-(2-fluoro-4-nitrophenyl)piperazin-1-yl)-6-methyl-2-oxocyclohex-3-ene-1-carboxylate 
• 1147846-98-7 methyl 4-(4-(2-fluoro-4-nitrophenyl)piperazin-1-yl)-2-oxo-6-phenylcyclohex-3-ene-1-carboxylate 
• 950821-44-0 2-(2,4-difluorophenyl)-1-[4-(2-fluoro-4-amino-phenyl)-piperazin-1-yl]-3-(1H-1,2,4-triazol-1-yl)-propan-2-ol 
• 1312759-97-9 N-(4-(4-[2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl]piperazin-1-yl)-3-fluoro-phenyl)acetamide 
• 1584804-01-2 [(2,2-dimethylpropanoyl)oxy]methyl (2S,5R,6R)-6-{[4-(2-fluoro-4-nitrophenyl)piperazin-1-yl]amino}penicillanate 

Relevant articles and documents

Novel 3-fluoro-4-morpholinoaniline derivatives: Synthesis and assessment of anti-cancer activity in breast cancer cells

Heterocyclic morpholine compounds are well-known for their anti-cancer activity. In this study, novel morpholine and its sulfonamide derivatives were designed and synthesized as potential anti-tumor agents. The new compounds were obtained from amine derivatives via nucleophilic addition reactions, providing the desired products in 70 to 90% yield. The docking analysis was performed for all thirty-one compounds. Out of them, we represent the docking poses for compounds NAM-5 and NAM-7 as representatives. After docking analysis, compounds NAM-5 and NAM- 7 were tested for in vitro antitumor activity against breast cancer cell lines (MCF-7 and MDA-MB-231) and healthy mouse embryonic fibroblast cell line (3T3L-1). Amongst these, sulfonamide group-containing compound NAM-5 showed significant anti-proliferative activity with IC50 of 1.811 μM and 2.143 μM for MCF-7 and MDA-MB-231 cells, respectively. On the other hand, NAM-7 showed good anti-proliferative activity against MCF-7 (IC50 1.883 μM) but slightly lower activity against MDA-MB-231 cells (IC50 4.688 μM). The activity of both the compound was also tested on 3T3L-1 Cell line which showed activity similar to clinically approved anti-cancer drug doxorubicin (DOX). The cell death analysis by flow-cytometry confirmed apoptosis mediated cell death in 3T3L-1, MCF-7 and MDA-MB-231 cells when treated with the NAM-5 and NAM-7, respectively. The results demonstrated that the synthesized sulfonamide derivatives have significant potential as anti-cancer agents and have a substantial importance in cancer therapeutics with favourable safety profile. Structural analysis of docked poses of sulfonamide derivatives attempts to shed light on the structural basis of sulfonamide derivatives based anti-cancer effect.

Oxazolidinone compound containing piperazine hydrazone structure

The invention discloses an oxazolidinone compound containing a piperazine hydrazone structure. The oxazolidinone compound comprises a compound shown as a general formula (I), or stereisomer thereof, or pharmaceutically-acceptable salt thereof, or solvate thereof or prodrug thereof, wherein R1 is hydrogen, fluorine, chlorine or trifluoromethyl, R2 is -NHCOCH3 or -OH, R3 is Ar which is C5-C10 aryl substituted by any 1-3 R4 and heteroaryl, and R4 is hydrogen, hydroxyl, halogen, nitro, amino, cyan, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkyl substituted by hydroxyl, amino or halogen, C1-C6 alkoxy substituted by hydroxyl, amino or halogen, amino substituted by mono- or bi-(C1-C6 alkyl), C1-C6 alkyl amido, free, salty, esterified and amidated hydroxyl, C1-C6 alkyl sulfinyl, C1-C6 alkyl sulfonyl, C1-C6 alkyl acyl and carbamoyl. The oxazolidinone compound can be used for preparing drug for treating microbial infection.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives

Research activities on the oxazolidinone antibacterial class of compounds continue to focus on developing newer derivatives with improved potency, broad-spectrum activity and safety profiles superior to linezolid. Among the safety concerns with the oxazolidinone antibacterial agents is inhibition of monoamine oxidases (MAO) resulting from their structural similarity with toloxatone, a known MAO inhibitor. Diverse substitution patterns at the C-5 position of the oxazolidinone ring have been shown to significantly affect both antibacterial activity and MAO inhibition to varying degrees. Also, the antibacterial activity of compounds containing iron-chelating functionalities, such as the hydroxamic acids, 8-hydroxyquinolines and catechols have been correlated to their ability to alter iron intake and/or metabolism. Hence a series of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives were synthesized and evaluated for their antibacterial and MAO-A and -B inhibitory activities. The compounds were devoid of significant antibacterial activity but most demonstrated moderate MAO-A and -B inhibitory activities. Computer modeling studies revealed that the lack of potent antibacterial activity was due to significant steric interaction between the hydroxamic acid N-OH oxygen atom and one of the G2540 5′-phosphate oxygen atoms at the bacterial ribosomal binding site. Therefore, the replacement of the 5-acetamidomethyl group of linezolid with the 5-(N-hydroxyacetamido)methyl group present in the hydroxamic acid oxazolidinone derivatives was concluded to be detrimental to antibacterial activity. Furthermore, the 5-(hydroxamic acid)methyl oxazolidinone derivatives were also less active as MAO-A and -B inhibitors compared with linezolid and the selective inhibitors clorgyline and pargyline. In general, the 5-(hydroxamic acid)methyl oxazolidinone derivatives demonstrated moderate but selective MAO-B inhibitory activity.

An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants

An azide-functionalised analogue of the oxazolidinone antibiotic linezolid was synthesised and shown to retain antimicrobial activity. Using facile 'click' chemistry, this versatile intermediate can be further functionalised to explore antimicrobial structure-activity relationships or conjugated to fluorophores to generate fluorescent probes. Such probes can report bacteria and their location in a sample in real time. Modelling of the structures bound to the cognate 50S ribosome target demonstrates binding to the same site as linezolid is possible. The fluorescent probes were successfully used to image Gram-positive bacteria using confocal microscopy.

Design, synthesis and biological activities of some 7-aminocephalosporanic acid derivatives

The treatment of 7-ACA with 4-substituted benzensulfonyl chlorides afforded the compounds containing 4-nitro/aminophenyl sulfonylamino moiety in the cephalosporanic acid skeleton (2, 4). The synthesis of the cephalosporanic acid derivatives containing 1,3

Discovery of a novel nitroimidazolyl-oxazolidinone hybrid with potent anti Gram-positive activity: Synthesis and antibacterial evaluation

A number of linezolid analogues containing a nitroaryl-1,3,4-thiadiazole moiety, were prepared and evaluated as antibacterial agents against a panel of Gram-positive and Gram-negative bacteria. Among synthesized compounds, nitrofuran analogue 1b exhibited more potent inhibitory activity, with respect to other synthesized compounds and reference drug linezolid. The target compounds were also assessed for their cytotoxic activity against normal mouse fibroblast (NIH/3T3) cells using MTT assay. The results indicated that compound 1c exhibit potent antibacterial activity against Gram-positive bacteria at non-cytotoxic concentrations.

Synthesis and antibacterial activities of eperezolid analogs with glycinyl substitutions

A series of eperezolid analogs with glycinyl substitutions were prepared and their antibacterial activities were studied against a panel of susceptible and resistant Gram-positive bacteria. The compounds with N-arylacyl or N-heteroarylacyl glycinyl struct

N-(3,4-disubstituted phenyl) salicylamide derivatives

A compound represented by the following formula (I) or a salt thereof: wherein R1, R2, R3 and R4 represent hydrogen atom, a halogen atom, cyano group, nitro group, a C1-4 alkyl group, a halogenated C

NOVEL TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to novel triazole compounds of formula (I), where all symbols are as defined in the detailed description; their pharmaceutically acceptable salts their stereosiomers thereof, their prodrugs, their rotamers, their pharmaceutical compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds.